Renal association clinical practice guideline on post-operative care of the kidney transplant recipient

Nephron - Clinical Practice

Volumn 118, Issue SUPPL. 1, 2011, Pages

  Baker, R ^a   Jardine, A ^b   Andrews, Peter ^c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b Department of Clinical Nephrology ^*  (United Kingdom)

^c SW Thames Renal and Transplantation Unit   (United Kingdom)

Author keywords

acute rejection; cardiovascular disease; chronic allograft injury; haematological complications; immunosuppression; infections; kidney transplantation; neoplasia; non adherence; reproductive issues

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; COTRIMOXAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISONIAZID; PYRIDOXINE;

ANEMIA; ARTICLE; BONE PAIN; CANCER SCREENING; CHRONIC ALLOGRAFT NEPHROPATHY; CONCEPTION; CONTRACEPTION; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DYSLIPIDEMIA; EPSTEIN BARR VIRUS INFECTION; GOUT; GRAFT RECIPIENT; HERPES SIMPLEX; HERPES ZOSTER; HYPERPARATHYROIDISM; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; INFECTION PREVENTION; ISCHEMIC HEART DISEASE; KAPOSI SARCOMA; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; MAINTENANCE THERAPY; MEDICAL SOCIETY; OSTEOPOROSIS; PATIENT CARE; POLYCYTHEMIA; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PREOPERATIVE CARE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SKIN CANCER; SMOKING CESSATION; VACCINATION;

GREAT BRITAIN; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NATIONAL HEALTH PROGRAMS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 79955828954     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000328074     Document Type: Article

References (166)

1. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl 3):S1-155
2. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2009
3. Health Do. Achieving excellence in kidney care: Delivering the National Service Framework for Renal Services. In: Health Do, ed. London; 2009
4. Reece SM, Harden PN, Smith AG, Ramsay HM. A model for nurse-led skin cancer surveillance following renal transplantation. Nephrol Nurs J 2002;29:257-259, 67
5. Short CD, Russell S, Valentine A. Clinical audit and long-term evaluation of renal transplant recipients. Transplantation 2001;72:S94-98
6. Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant 2004;19:3144-3149 (Pubitemid 40057641)
7. Tong A, Howell M, Wong G, Webster AC, Howard K, Craig JC. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant 2010
8. Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol 2010;5:1305-1311
9. O'Grady JG, Asderakis A, Bradley R, et al. Multidisciplinary insights into optimizing adherence after solid organ transplantation. Transplantation 2010;89:627-632
10. de Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001;12:1538-1546 (Pubitemid 32666338)
11. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7:2619-2625 (Pubitemid 47561615)
12. Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009;360: 2683-2685
13. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810
14. Rowshani AT, Scholten EM, Bemelman F, et al.No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimustreated renal transplant recipients at one year. J Am Soc Nephrol 2006;17:305-312
15. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003;3:590-598 (Pubitemid 36612842)
16. Vadivel N, Garg A, Holt DW, Chang RW, MacPhee IA. Tacrolimus dose in black renal transplant recipients. Transplantation 2007;83:997-999 (Pubitemid 46682745)
17. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009;9:1876-1885
18. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562-2575 (Pubitemid 350294223)
19. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999;68:391-396
20. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone vs. tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc 1999;31:1134 (Pubitemid 29127842)
21. Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009;87:785-794
22. Shehata M, Bhandari S, Venkat-Raman G, et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl Int 2009;22:821-830
23. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008;248:564-577
24. Matas AJ, Gillingham K, Kandaswamy R, et al. Kidney transplant halflife (t[1/2]) after rapid discontinuation of prednisone. Transplantation 2009;87:100-102
25. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005;5:2473-2478
26. Humar A, Gillingham K, Kandaswamy R, Payne W, Matas A. Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant 2007;7:1948-1953 (Pubitemid 47037993)
27. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008;85:1675-1685
28. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and metaanalysis of randomized trials. Transplantation 2006;81:1234-1248
29. Morath C, Arns W, Schwenger V, et al. Sirolimus in renal transplantation. Nephrol Dial Transplant 2007;22(Suppl 8):viii61-viii65
30. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant 2009;9:1495-1499
31. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001;72:1181-1193 (Pubitemid 33026593)
32. Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reducedexposure cyclosporine in de novo kidney transplantation. Ther Drug Monit 2004;26:499-505 (Pubitemid 39314317)
33. Johnston A, Belitsky P, Frei U, et al. Potential clinical implications of substitution of generic cyclosporine formulations for cyclosporine microemulsion (Neoral) in transplant recipients. Eur J Clin Pharmacol 2004;60:389-395 (Pubitemid 39214891)
34. Colvin RB, Cohen AH, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997;8:1930-1941
35. Solez K, Colvin RB, Racusen LC, et al. Banff '07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753-760 (Pubitemid 351347767)
36. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7:518-526 (Pubitemid 46376465)
37. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria - an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003;3:708-714 (Pubitemid 36745243)
38. Racusen LC, Solez K, Colvin RB, et al. The Banff '97 working classification of renal allograft pathology. Kidney Int 1999;55:713-723 (Pubitemid 29082898)
39. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993;44:411-422 (Pubitemid 23228698)
40. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007;7:2538-2545 (Pubitemid 47561621)
41. Rush D. Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin J Am Soc Nephrol 2006;1:138-143
42. Nickerson P, Jeffery J, Gough J, et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. J Am Soc Nephrol 1999;10:1801-1805 (Pubitemid 29364680)
43. Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation 2006;81:953-965 (Pubitemid 43670421)
44. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation 2001;71:1091-1097
45. Beimler J, Zeier M. Borderline rejection after renal transplantation - to treat or not to treat. Clin Transplant 2009;23(Suppl 21):19-25
46. Nemeth D, Ovens J, Opelz G, et al. Does borderline kidney allograft rejection always require treatment? Transplantation 2010;8:8
47. BSHI/BTS. Guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation. 2010
48. Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibodymediated renal allograft injury: implications for treatment. Am J Transplant 2008;8:1367-1373 (Pubitemid 351989489)
49. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005;5:2611-2618
50. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-2333 (Pubitemid 37509740)
51. Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009;20:2490-2492
52. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009;9:527-535
53. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a fiveyear longitudinal study. Am J Transplant 2007;7:864-871 (Pubitemid 46481194)
54. Terasaki P, Mizutani K. Antibody mediated rejection: update 2006. Clin J Am Soc Nephrol 2006;1:400-403
55. Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002;13:1091-1099 (Pubitemid 34274108)
56. Kedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant 2009;9:812-819
57. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009;87:1505-1513
58. Worthington JE, Martin S, Al-Husseini DM, Dyer PA, Johnson RW. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003;75: 1034-1040 (Pubitemid 36438534)
59. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the 'creeping creatinine' study. Transplantation 2005;79:466-475 (Pubitemid 40280180)
60. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002;346:580-590 (Pubitemid 34438820)
61. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233-242
62. Winkelmayer WC, Chandraker A. Pottransplantation Anemia: Management and Rationale. Clin J Am Soc Nephrol 2008;3:S49-55
63. Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007;7:2748-2756 (Pubitemid 350045780)
64. Cherukuri A, Welberry-Smith MP, Tattersall JE, et al. The clinical significance of early proteinuria after renal transplantation. Transplantation 2010;89:200-207
65. Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005;5:2281-2288 (Pubitemid 41648477)
66. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. Jama 2000;283:633-638 (Pubitemid 30069179)
67. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005;5:2725-2731
68. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998;53:217-222 (Pubitemid 28066925)
69. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004;43:1071-1081 (Pubitemid 38691503)
70. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2:807-818 (Pubitemid 36306835)
71. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006;17:889-899
72. Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010;25:967-976
73. Cross NB, Webster AC, Masson P, O'Connell P J, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and metaanalysis of randomized controlled trials. Transplantation 2009;88:7-18
74. Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001;72:1787-1792 (Pubitemid 33144233)
75. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001;72:777-786 (Pubitemid 32879845)
76. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010;89:1-14
77. Srinivas TR, Meier-Kriesche H-U. Minimizing Immunosuppression, an Alternative Approach to Reducing Side Effects: Objectives and Interim Result. Clin J Am Soc Nephrol 2008;3:S101-116
78. Jardine AG, Fellstrom B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005;46:529-536 (Pubitemid 41208190)
79. Pilmore H. Cardiac assessment for renal transplantation. Am J Transplant 2006;6:659-665 (Pubitemid 43345002)
80. Pilmore H, Dent H, Chang S, McDonald SP, Chadban SJ. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010;89:851-857
81. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003;14:462-468 (Pubitemid 36150871)
82. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000;11:1735-1743
83. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
84. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-1307
85. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-2031 (Pubitemid 36695044)
86. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003;163:553-564 (Pubitemid 36314342)
87. Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006;6:770-774 (Pubitemid 43345015)
88. Langone AJ, Chuang P. Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors. Transplantation 2006;81:804-807
89. Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006;6:205-208 (Pubitemid 43382220)
90. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4(Suppl 7):13-53 (Pubitemid 38436863)
91. Johnston O, Rose CL,Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-1418
92. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007;7:1506-1514 (Pubitemid 46776239)
93. Vincenti F, Schena FP, Paraskevas S, Hauser IA,Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008;8:307-316
94. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005;19:291-298 (Pubitemid 40711959)
95. Wong G, Howard K,Webster A, Chapman JR, Craig JC. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation 2009;87:1078-1091
96. NHS Cancer Screening Programmes. 2010. (Accessed 10/12/2010, 2010, at http://www.cancerscreening.nhs.uk/index.html.)
97. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76:1289-1293 (Pubitemid 37430713)
98. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883-889 (Pubitemid 41552882)
99. Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010;10:1385-1393
100. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-1323 (Pubitemid 40411498)
101. Chow J, Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis 2009;49:1550-1556
102. DOH. Health information for overseas travel. 2010
103. Kotton CN, Hibberd PL. Travel medicine and the solid organ transplant recipient. Am J Transplant 2009;9(Suppl 4):S273-281
104. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S78-86
105. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-795
106. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365:2105-2115 (Pubitemid 40826968)
107. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462-1470 (Pubitemid 29220545)
108. Humar A, Asberg A, Kumar D, et al. An assessment of herpesvirus coinfections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009;9:374-381
109. van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010;89:320-326
110. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228-1237
111. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009;20:2449-2458
112. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009;9:1205-1213
113. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106-2113 (Pubitemid 47247057)
114. Avery RK. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved? Am J Transplant 2007;7:2062-2063 (Pubitemid 47247064)
115. Allen U, Preiksaitis J. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S87-96
116. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of posttransplant lymphoproliferative disease. Transpl Infect Dis 2001;3:79-87 (Pubitemid 32452922)
117. Heininger U, Seward JF. Varicella. Lancet 2006;368:1365-1376 (Pubitemid 44540319)
118. Pergam SA, Limaye AP. Varicella zoster virus (VZV) in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S108-115
119. Fehr T, Rusi B, Fischer A, Hopfer H, Wuthrich RP, Gaspert A. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009;87:1837-1841
120. Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S97-100
121. Other herpesviruses: HHV-6, HHV-7, HHV-8, HSV-1 and -2, VZV. Am J Transplant 2004;4(Suppl 10):66-71
122. Dall A, Hariharan S. BKvirus nephritis after renal transplantation. Clin J Am Soc Nephrol 2008;3:S68-75
123. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 2009;87:621-630
124. Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol 2007;2(Suppl 1):S36-46
125. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002;347:488-496 (Pubitemid 34879336)
126. Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004;4:2082-2092 (Pubitemid 39611638)
127. Hirsch HH, Randhawa P. BKvirus in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4):S136-146
128. Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant 2010;10:407-415
129. Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation 2010;89:1462-1465
130. Pallet N, BurgardM, Quamouss O, et al. Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation 2010;89:1542-1544
131. Gabardi S, Waikar SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 2010;5:1298-1304
132. Maggiore U, Medici MC, Vaglio A, Buzio C. Increased viral load after intravenous immunoglobulin therapy for BK virus-associated nephropathy. Transpl Infect Dis 2010
133. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010;89:1057-1070
134. Dharnidharka VR, Cherikh WS, Neff R, Cheng Y, Abbott KC. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant 2010;10:1312-1315
135. Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim- sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 1990;89:255-274 (Pubitemid 20323251)
136. Treatment of tuberculosis. MMWR Recomm Rep 2003;52:1-77
137. Currie AC, Knight SR, Morris PJ. Tuberculosis in Renal Transplant Recipients: The Evidence for Prophylaxis. Transplantation 2010
138. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int(Suppl 2009):S1-130
139. Akaberi S, Simonsen O, Lindergard B, Nyberg G. Can DXA predict fractures in renal transplant patients? Am J Transplant 2008;8:2647-2651
140. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000;11:1093-1099 (Pubitemid 30367939)
141. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010;6:82-88
142. Guidelines Working Group for the Bone and Tooth Society NOSaRCoP. Glucocorticoid induced osteoporosis: guidelines for prevention and treatment. London; 2002
143. Borchhardt K, Sulzbacher I, Benesch T, Fodinger M, Sunder- Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007;7:2515-2521 (Pubitemid 47561599)
144. Kandil E, Florman S, Alabbas H, et al. Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci 2010;339:420-424
145. Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005;20:1714-1720 (Pubitemid 41418599)
146. Serra AL, Braun SC, Starke A, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 2008;8:803-810 (Pubitemid 351347748)
147. Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation 2005;80:1383-1391 (Pubitemid 41803617)
148. Collini A, De Bartolomeis C, Barni R, Ruggieri G, Bernini M, Carmellini M. Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int 2006;70:1367-1370 (Pubitemid 44435191)
149. Grotz WH, Breitenfeldt MK, Braune SW, et al. Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation. Transpl Int 2001;14:16-23 (Pubitemid 32125876)
150. IV. Clinical practice recommendations for anemia in chronic kidney disease in transplant recipients. Am J Kidney Dis 2006;47:S109-116
151. Julian BA, Gaston RS, Barker CV, Krystal G, Diethelm AG, Curtis JJ. Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Kidney Int 1994;46:1397-1403 (Pubitemid 24330720)
152. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int 2003;63:1187-1194 (Pubitemid 36349983)
153. Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2009:103-122
154. Sibanda N, Briggs JD, Davison JM, Johnson RJ, Rudge CJ. Pregnancy after organ transplantation: a report from the UK Transplant pregnancy registry. Transplantation 2007;83:1301-1307 (Pubitemid 46800304)
155. Watnick S, Rueda J. Reproduction and contraception after kidney transplantation. Curr Opin Obstet Gynecol 2008;20:308-312 (Pubitemid 351643520)
156. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006;82:1698-1702 (Pubitemid 46035654)
157. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009; 149A:1241-1248
158. Pisoni CN, D'Cruz DP. The safety of mycophenolate mofetil in pregnancy.
159. Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception 2010;82:102-112
160. Armenti VT, Daller JA, Constantinescu S, et al. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Clin Transpl 2006:57-70
161. Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007;20:305-311
162. Deutsch MA, Kaczmarek I, Huber S, et al. Sirolimus-associated infertility: case report and literature review of possible mechanisms. Am J Transplant 2007;7:2414-2421 (Pubitemid 47347852)
163. Bererhi L, Flamant M, Martinez F, Karras A, Thervet E, Legendre C. Rapamycin-induced oligospermia. Transplantation 2003;76:885-886
164. Malavaud B, Rostaing L, Rischmann P, Sarramon JP, Durand D. High prevalence of erectile dysfunction after renal transplantation. Transplantation 2000;69:2121-2124 (Pubitemid 30395046)
165. Filocamo MT, Zanazzi M, Li Marzi V, et al. Sexual dysfunction in women during dialysis and after renal transplantation. J Sex Med 2009;6:3125-3131
166. Sharma RK, Prasad N, Gupta A, Kapoor R. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. Am J Kidney Dis 2006;48:128-133